US Stocks Movement | AstraZeneca (AZN.US) rises over 2% as Goldman Sachs is bullish, raising price target to $99
According to Jinse Finance APP, on Wednesday, AstraZeneca (AZN.US) rose more than 2%, closing at $81.99. Recently, Goldman Sachs released a research report stating that AstraZeneca announced positive results for Baxdrostat in the Phase III BaxHTN clinical trial at the 2025 European Society of Cardiology (ESC) annual meeting. Baxdrostat demonstrated strong efficacy in treating hypertension during the clinical trial and is expected to bring AstraZeneca sales opportunities worth several billions of dollars. Goldman Sachs has given AstraZeneca a "Buy" rating, with a 12-month target price of $99. This target price represents an upside of about 23% compared to the stock's closing price of $80.19 on Tuesday.
According to the information, Baxdrostat is a highly selective aldosterone synthase inhibitor (ASI) that targets one of the hormones responsible for increased blood pressure and elevated cardiovascular and renal risks. Currently, the drug is undergoing clinical trials worldwide, with more than 20,000 patients enrolled. The trials include monotherapy for hypertension and primary aldosteronism, combination therapy with dapagliflozin for chronic kidney disease and hypertension, as well as prevention of heart failure in hypertensive patients. It is reported that Baxdrostat is expected to be approved in the US and Europe in the first half of 2026, becoming the world's first marketed aldosterone synthase inhibitor (ASI) antihypertensive drug.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Market Preview | Major Index Futures Mixed, Tesla Rises Premarket, Waller Boosts Expectations for Fed to Hold Rates Steady in October
Before the US stock market opens on October 16 (Friday), the three major US stock index futures showed mixed movements.
QuantumScape stock gains 7.63%, but stays below all three daily EMAs
JPMorgan comments on the Roadster launch: Tesla (TSLA.US) aims to showcase engineering capabilities rather than a commercialization plan, maintaining a "Neutral" rating
After the Roadster launch event, JPMorgan reiterated its "neutral" rating on Tesla.
MSCI downgrade alert triggers foreign capital flight concerns! Indonesia suffers triple blow in stocks, bonds, and currency as stock market sees worst decline in nearly 30 years
After MSCI, the index compilation agency, expressed consideration of downgrading Indonesia's stock market rating and removing it from global indices, concerns about capital outflows triggered a triple sell-off in Indonesia's stocks, bonds, and currency.
Crypto prices
More
